Dr. Cowan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
617 Eastlake Ave E
Seattle, WA 98109Phone+1 206-606-7348Fax+1 206-606-1043- Is this information wrong?
Summary
- As an associate professor of medicine in the Div. of Medical Oncology at the University of Washington School of Medicine, my focus is in plasma cell disorders, specifically, MM and AL amyloidosis. I am involved in a variety of clinical research projects, both retrospective and prospective studies. I have a special interest in multiple myeloma and AL amyloidosis.
My clinical and research focus is on immunotherapy for MM, including CAR T cells; health services research in MM, and health informatics.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2012 - 2015
Boston University Medical CenterResidency, Internal Medicine, 2009 - 2011- Boston University Medical CenterInternship, Internal Medicine, 2008 - 2009
- University of Washington School of MedicineClass of 2008
Certifications & Licensure
WA State Medical License 2017 - 2025
AK State Medical License 2022 - 2024
MA State Medical License 2011 - 2013- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Start of enrollment: 2016 Aug 29
- A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Start of enrollment: 2017 Nov 07
- A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2018 Apr 02
- Join now to see all
Publications & Presentations
PubMed
- Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final ana...Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderso...> ;The Lancet. Haematology. 2023 Sep 11
- γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, ...Andrew J Cowan, Margot J Pont, Blythe D Sather, Cameron J Turtle, Brian G Till, Edward N Libby 3rd, David G Coffey, Sherilyn A Tuazon, Brent Wood, Ted Gooley, Vicky Q ...> ;The Lancet. Oncology. 2023 Jul 1
- 3 citationsHumoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapy.Michael A Gonzalez, Atif M Bhatti, Kristin Fitzpatrick, Jim Boonyaratanakornkit, Meei-Li Huang, Victoria L Campbell, Jessica Hecht, Sarah Ibrahimi, Shera N Wanner, Dam...> ;Blood Advances. 2023 May 9
- Join now to see all
Abstracts/Posters
- Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma SecretaseAndrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Clinical Challenges: Quadruplet Therapy in Multiple MyelomaJune 1st, 2021
Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019
Grant Support
- T32 Oncology Training GrantNIH2014–2015
Committees
- Reviewer, Scientific Review Committee, FHCRC 2016 - Present
Professional Memberships
- Member
- Fellow
Hospital Affiliations
UW Medicine/Harborview Medical CenterSeattle, Washington
Fred Hutchinson Cancer CenterSeattle, Washington
External Links
- HemOnc.orghttp://hemonc.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
